|10th July 2020||William G. Rice||168,891||Open or private sale||$6.05||$1,021,790.55|
|10th July 2020||Gregory K. Chow||126,668||Open or private sale||$6.05||$766,341.40|
|10th July 2020||Jotin Marango||62,835||Open or private sale||$6.05||$380,151.75|
|2nd July 2020||Jotin Marango||20,946||Open or private sale||$6.34||$132,793.45|
|24th June 2020||Warren Whitehead||12,000||Open or private sale||$6.73||$80,760.00|
|24th June 2020||Warren Whitehead||5,000||Open or private sale||$6.78||$33,900.00|
|24th June 2020||Warren Whitehead||7,000||Exercise of derivative||$2.60||$18,200.00|
|24th June 2020||Warren Whitehead||5,000||Exercise of derivative||$1.02||$5,100.00|
|23rd June 2020||Warren Whitehead||500||Exercise of derivative||$1.60||$800.00|
|23rd June 2020||Warren Whitehead||10,000||Exercise of derivative||$1.12||$11,200.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Aptose Biosciences, Inc. is a clinical-stage oncology company. The company engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes.